Kenvue Inc (KVUE)
適正価値ファンダメンタル
62
株価
$17.37
時価総額
$34.34B
パート1 · 企業の価値
概要
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users
The only competitor Kenvue lists in all three of its segments, with Vicks and Pepto-Bismol against Self Care, Olay against Neutrogena and Aveeno, and Crest and Always against Listerine and Stayfree.
The other large pure-play consumer health company, named by Kenvue in its own 10-K, competing for the same pharmacy and supermarket shelves in pain relief, oral care and cold and allergy remedies worldwide.
Named in Kenvue's 10-K as a Self Care rival: Nurofen, Mucinex and Strepsils go head to head with Tylenol, Motrin and Zyrtec in over-the-counter pain, cold and allergy products.
Named by Kenvue among its Skin Health and Beauty rivals: Nivea and Eucerin compete with Neutrogena and Aveeno for the same mass-market face and body care shopper.
Named in the same segment of Kenvue's 10-K: its mass brands, such as L'Oréal Paris, Garnier and CeraVe, fight for the same skincare and haircare shelf space as Neutrogena, Aveeno and OGX.
The largest maker of store-brand over-the-counter medicines in the United States, the private-label competition Kenvue's 10-K cites in every segment, selling the same active ingredients as Tylenol or Zyrtec at a lower price in the same aisle.
貸借対照表と流動性
売上高
$15.41B
直近12か月（2026/6/28まで）
純利益
$1.66B
直近12か月（2026/6/28まで）
フリーキャッシュフロー
$1.72B
自己資本合計
$10.77B
負債合計
$16.31B
流動比率
1.01
利払い倍率
6.19
負債/EBITDA
2.90
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$20.84
現在株価
$17.37
安全マージン
+16.7%
適正価値レンジ
$13.54 - $28.13
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
20.53
ROE
13.7%
P/B レシオ
3.21
P/FCF
17.72
粗利益率
58.2%
ROIC
10.0%
収益性レーダー
価値創造（経済的モート）
ROIC
10.0%
WACC
7.2%
ROIC − WACC
+2.8 pp
ROICが資本コストを上回っています。企業は株主のために価値を創出しています。
ファンダメンタル分析基準
合格（17）
- ROIC 10.0%
- Gross Margin 58.2%
- P/FCF 17.72
- Debt/Equity ratio
- Operating Margin 17.1%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.6%
- Earnings Surprise avg 9.5%
- Earnings Quality (OCF/NI) 1.40
- Share Dilution 1.4%
- Net Margin Trend 10.8% vs 9.4%
- Piotroski F-Score 6/9
不合格（9）
- EPS shows upward trend
- EPS CAGR -10.98%
- Price CAGR -6.18%
- P/B Ratio 3.21
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 0.9%
- Analyst Consensus 30% Buy
データなし（2）
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式数は安定している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Kirk L. Perry | CEO & Director | 58 |
| Mr. Michael P. Wondrasch | Chief Technology & Data Officer | 56 |
| Mr. Matthew Orlando | General Counsel | 48 |
| Mr. Carlton Lawson | Group President of Europe, Middle East & Africa | 56 |
| Ms. Heather R. Howlett | Interim CFO & Chief Accounting Officer | 47 |
| Ms. Meredith Stevens | Chief Operations Officer | 62 |
| Dr. Caroline Tillett Ph.D. | Chief Scientific Officer | 53 |
| Ms. Sofya Tsinis | Head of Investor Relations | - |
| Mr. Jonathan Halvorson | Chief Digital & Marketing Officer | 42 |
| Mr. Anil Agarwal | Head of Total Rewards | - |
監査リスク
4
取締役会リスク
3
報酬リスク
6
株主権利リスク
7
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for KVUE, sourced from Markets Gazette.